In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex-Reference-Cited by-同舟云学术

In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex

Published:1995-08 Issue:8 Volume:39 Page:1862-1863
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Meyer S C¹,Majumder S K¹,Cynamon M H¹

Affiliation:

1. State University of New York Health Science Center, Syracuse 13210, USA.

Abstract

PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite were evaluated for in vitro activity against 31 clinical Mycobacterium avium complex isolates. Broth dilution MICs of PS-15 ranged from 16 to 64 micrograms/ml. The cyclic metabolite was three to five times more active than the parent compound. Further evaluation of these compounds in an M. avium-infected murine test system will be of interest.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.39.8.1862

Reference6 articles.

1. Canfield C. J. 1986. New antimalarials under development p. 99-100. In L. J. Bruce-Chwatt (ed.) Chemotherapy of malaria vol 27. World Health Organization Geneva.

2. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists;Canfield C. J.;Am. J. Trop. Med. Hyg.,1993

3. Evaluation of WR250417 (a proguanil analog) for causal prophylactic activity in the Plasmodium cynomolgi-Macaca mulatta model;Edstein M. D.;Am. J. Trop. Med. Hyg.,1994

4. Prophylaxis for opportunistic infections in patients with HIV infection;Gallant J. E.;Ann. Intern. Med.,1994

5. Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist;Hughes W. T.;Antimicrob. Agents Chemother.,1993

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR;RSC Medicinal Chemistry;2021

2. Design, Synthesis, Antitubercular and Antibacterial Activities of 1,3,5-Triazinyl Carboxamide Derivatives and In Silico Docking Studies;Russian Journal of General Chemistry;2020-07

3. Mycobacterium tuberculosis Folate Metabolism and the Mechanistic Basis forpara-Aminosalicylic Acid Susceptibility and Resistance;Antimicrobial Agents and Chemotherapy;2015-06-01

4. Synthesis and antimicrobial activity of N1-benzyl or N1-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamines;Bioorganic & Medicinal Chemistry Letters;2011-09

5. Discovery of new 1,3,5-triazine scaffolds with potent activity against Mycobacterium tuberculosis H37Rv;European Journal of Medicinal Chemistry;2010-08